Burjeel Holdings PLC (ADX: BURJEEL) posted a 129% jump in net profit to AED 148 million for Q2 2025, powered by strong revenue growth, efficiency gains, and expansion across high-value specialties.
Key Highlights (Q2 2025):
- Revenue: AED 1.4 billion (+18.7%), supported by higher patient footfall (+12.1%) and advanced services.
- EBITDA: AED 306 million (+59.4%), with margins improving to 21.8%.
- Oncology: Revenue rose 36.7% as the Group expanded its cancer care network, including the new Burjeel Cancer Institute clinics and UAE’s first dedicated cancer pharmacy.
- Dividend: AED 170 million declared for FY2024 (47% payout).
Strategic Moves:
- Expanded oncology, fertility, mental health (via Alkalma JV), and physiotherapy (PhysioTherabia acquisition in Riyadh).
- Acquired Medeor Hospital Dubai building for AED 170 million, improving cost structure.
- Launched new centers, including Saadiyat Island Medical Center and specialized services like the Osseointegration Clinic and Epilepsy Monitoring Unit.
- Introduced DOCKTOUR with AD Ports Group to deliver care in underserved regions.
CEO John Sunil emphasized Burjeel’s momentum in complex care, digital health integration, and value-based partnerships:
“Net profit growth of 129% reinforces our long-term strategy. We are building the region’s largest private oncology network while scaling fertility, mental health, and advanced diagnostics.”
Performance by Segment:
- Hospitals: Contributed 89% of revenue (AED 1.25 billion, +17.3%).
- Medical Centers: Revenue rose 36.8% to AED 121 million, fueled by 45+ new centers.
- Burjeel Medical City (BMC): Revenue up 14.7% to AED 333 million, with bed occupancy at 68% and EBITDA margin at 17.6%.
Financial Position:
Operating cash flow grew 8.1% in H1 2025, while growth CAPEX reached AED 403 million. Net debt / EBITDA stood at 1.8x, keeping the balance sheet flexible for expansion.
Burjeel reaffirmed its dividend policy of 40–70% net income payout, balancing shareholder returns with aggressive investment in high-growth specialties and regional expansion.
